{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:36:34Z","timestamp":1789673794140,"version":"4.0.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012353","name":"Deutschen Konsortium f\u00fcr Translationale Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite the successful development of vaccines and neutralizing antibodies to limit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerging variants prolong the pandemic and emphasize the persistent need to develop effective antiviral treatment regimens. Recombinant antibodies directed to the original SARS-CoV-2 have been successfully used to treat established viral disease. However, emerging viral variants escape the recognition by those antibodies. Here we report the engineering of an optimized ACE2 fusion protein, designated ACE2-M, which comprises a human IgG1 Fc domain with abrogated Fc-receptor binding linked to a catalytically-inactive ACE2 extracellular domain that displays increased apparent affinity to the B.1 spike protein. The affinity and neutralization capacity of ACE2-M is unaffected or even enhanced by mutations present in the spike protein of viral variants. In contrast, a recombinant neutralizing reference antibody, as well as antibodies present in the sera of vaccinated individuals, lose activity against such variants. With its potential to resist viral immune escape ACE2-M appears to be particularly valuable in the context of pandemic preparedness towards newly emerging coronaviruses.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1112505","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T06:10:53Z","timestamp":1678255853000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro"],"prefix":"10.3389","volume":"14","author":[{"given":"Latifa","family":"Zekri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Ruetalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Manz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Georg","family":"Rammensee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundram","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20210008","DOI":"10.1098\/rsfs.2021.0008","article-title":"The SARS-CoV-2 pandemic: Remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome","volume":"11","author":"Anderson","year":"2021","journal-title":"Interface Focus"},{"key":"B2","article-title":"Features, evaluation, and treatment of coronavirus (COVID-19)","author":"Cascella","year":"2022","journal-title":"StatPearls [Internet]."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.752227","article-title":"Beyond vaccines: Clinical status of prospective COVID-19 therapeutics","volume":"12","author":"Kumar","year":"2021","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"109433","DOI":"10.1016\/j.celrep.2021.109433","article-title":"A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations","volume":"36","author":"Bertoglio","year":"2021","journal-title":"Cell Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1038\/s41467-021-25030-7","article-title":"Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19","volume":"12","author":"Nouailles","year":"2021","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00836-z","article-title":"Increased immune escape of the new SARS-CoV-2 variant of concern omicron","volume":"19","author":"Hu","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.126","article-title":"SARS-CoV-2 omicron variant: Immune escape and vaccine development","volume":"3","author":"Ao","year":"2022","journal-title":"MedComm"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn8652","article-title":"Structural basis of SARS-CoV-2 omicron immune evasion and receptor engagement","volume":"375","author":"McCallum","year":"2022","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2021.07.026","article-title":"Binding affinity and mechanisms of SARS-CoV-2 variants","volume":"19","author":"Han","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.1038\/s41467-021-26401-w","article-title":"Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30418-5","article-title":"Human recombinant soluble ACE2 in severe COVID-19","volume":"8","author":"Zoufaly","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s13738-020-02049-z","article-title":"The ACE2 as a \u201crescue protein\u201d or \u201csuspect enzyme\u201d in COVID-19: possible application of the \u201cengineered inactive hrsACE2\u201d as a safer therapeutic agent in the treatment of SARS-CoV-2 infection","volume":"18","author":"Khodarahmi","year":"2020","journal-title":"J Iran Chem Soc"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e11902","DOI":"10.15252\/emmm.201911902","article-title":"An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer","volume":"13","author":"Zekri","year":"2021","journal-title":"EMBO Mol Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.chom.2020.04.004","article-title":"An infectious cDNA clone of SARS-CoV-2","volume":"27","author":"Xie","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.01145-20","article-title":"Antibody response against SARS-CoV-2 and seasonal coronaviruses in nonhospitalized COVID-19 patients","volume":"6","author":"Ruetalo","year":"2021","journal-title":"mSphere"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s41467-021-20973-3","article-title":"Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-ab to evaluate endemic coronavirus cross-reactivity","volume":"12","author":"Becker","year":"2021","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311191200","article-title":"ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis","volume":"279","author":"Towler","year":"2004","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2005.04756.x","article-title":"Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis","volume":"272","author":"Guy","year":"2005","journal-title":"FEBS J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc0870","article-title":"Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2","volume":"369","author":"Chan","year":"2020","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04442-5","article-title":"Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 omicron","volume":"603","author":"Shuai","year":"2022","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04474-x","article-title":"Altered TMPRSS2 usage by SARS-CoV-2 omicron impacts infectivity and fusogenicity","volume":"603","author":"Meng","year":"2022","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00619-9","article-title":"Reduced interferon antagonism but similar drug sensitivity in omicron variant compared to delta variant of SARS-CoV-2 isolates","volume":"32","author":"Bojkova","year":"2022","journal-title":"Cell Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","article-title":"The significant immune escape of pseudotyped SARS-CoV-2 variant omicron","volume":"11","author":"Zhang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02844-0","article-title":"Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum","volume":"399","author":"Dejnirattisai","year":"2022","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.20.473557","article-title":"mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant","author":"Edara","year":"2021","journal-title":"bioRxiv"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1175516\/v1","article-title":"An infectious SARS-CoV-2 B.1.1.529 omicron virus escapes neutralization by therapeutic monoclonal antibodies","author":"VanBlargan","year":"2021","journal-title":"Res Sq"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola Virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J Virol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/psp4.12364","article-title":"Reducing palivizumab dose requirements through rational dose regimen design","volume":"8","author":"Reuter","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"105271","DOI":"10.1016\/j.antiviral.2022.105271","article-title":"ACE2-fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern","volume":"199","author":"Tsai","year":"2022","journal-title":"Antiviral Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"eabn4188","DOI":"10.1126\/sciadv.abn4188","article-title":"Engineered ACE2-fc counters murine lethal SARS-CoV-2 infection through direct neutralization and fc-effector activities","volume":"8","author":"Chen","year":"2022","journal-title":"Sci Adv"},{"key":"B45","doi-asserted-by":"publisher","first-page":"105147","DOI":"10.1016\/j.antiviral.2021.105147","article-title":"A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency","volume":"194","author":"Leach","year":"2021","journal-title":"Antiviral Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.836232","article-title":"Multiple SARS-CoV-2 variants exhibit variable target cell infectivity and ability to evade antibody neutralization","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-020-00426-x","article-title":"CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-00460-y","article-title":"AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells","volume":"31","author":"Wang","year":"2021","journal-title":"Cell Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41422-021-00595-6","article-title":"Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2","volume":"32","author":"Gu","year":"2022","journal-title":"Cell Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108375","article-title":"Identification of lectin receptors for conserved SARS-CoV-2 glycosylation sites","volume":"40","author":"Hoffmann","year":"2021","journal-title":"EMBO J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-021-1990-5","article-title":"Genome-wide CRISPR activation screen identifies candidate receptors for SARS-CoV-2 entry","volume":"65","author":"Zhu","year":"2022","journal-title":"Sci China Life Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1112505\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T06:10:57Z","timestamp":1678255857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1112505\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2023.1112505"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1112505","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"article-number":"1112505"}}